Literature DB >> 21458682

Implications for vancomycin-resistant Enterococcus colonization associated with Clostridium difficile infections.

Shigeki Fujitani1, W Lance George, Margie A Morgan, Stephen Nichols, A Rekha Murthy.   

Abstract

BACKGROUND: Vancomycin-resistant Enterococcus (VRE) colonization of the gastrointestinal tract shares similar risk factors with Clostridium difficile infection. We sought to elucidate the prevalence and risk factors of VRE colonization associated with C difficile infection.
METHODS: All adult inpatients with C difficile infection from July 2006 to October 2006 were prospectively evaluated. All C difficile toxin-positive stool samples were screened for detection of VRE. Risk factors for VRE colonization were compared in patients with C difficile infection with and without VRE colonization.
RESULTS: Of the 158 cases of C difficile infection evaluated, 88 (55.7%) involved VRE colonization. Independent risk factors for VRE colonization were admission from long-term care facilities (P = .013), dementia (P = .017), and hospitalization in the previous 2 months (P = .014). No statistically significant difference between C difficile infection cases with and without VRE colonization in terms of previous receipt (within 1 month) of antibiotics, including metronidazole and vancomycin, was found on multivariate analysis. C difficile infection cases with VRE colonization had a higher prevalence of coinfection with methicillin-resistant Staphylococcus aureus (P = .002) and Acinetobacter spp (P = .006).
CONCLUSION: VRE colonization was associated with >50% of C difficile infection cases and with a higher rate of coinfection with multidrug-resistant pathogens. Given the high rate of C difficile infection associated with VRE colonization, active surveillance of VRE in patients with C difficile infection is reasonable in high-risk settings.
Copyright © 2011 Association for Professionals in Infection Control and Epidemiology, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21458682     DOI: 10.1016/j.ajic.2010.10.024

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  19 in total

1.  Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.

Authors:  Diane M Citron; Kerin L Tyrrell; Suzanne E Dale; Laurent Chesnel; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

2.  Adherence to clinical practice guidelines for the management of Clostridium difficile infection in Japan: a multicenter retrospective study.

Authors:  K Kobayashi; N Sekiya; Y Ainoda; H Kurai; A Imamura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-02       Impact factor: 3.267

Review 3.  Computational approaches to understanding Clostridioides difficile metabolism and virulence.

Authors:  Matthew L Jenior; Jason A Papin
Journal:  Curr Opin Microbiol       Date:  2021-11-25       Impact factor: 7.934

4.  Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical center.

Authors:  Bryan F Curtin; Yousef Zarbalian; Mark H Flasar; Erik von Rosenvinge
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

5.  Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.

Authors:  Glen P Carter; Anjana Chakravorty; Tu Anh Pham Nguyen; Steven Mileto; Fernanda Schreiber; Lucy Li; Pauline Howarth; Simon Clare; Bliss Cunningham; Susan P Sambol; Adam Cheknis; Iris Figueroa; Stuart Johnson; Dale Gerding; Julian I Rood; Gordon Dougan; Trevor D Lawley; Dena Lyras
Journal:  MBio       Date:  2015-06-02       Impact factor: 7.867

6.  Insights into the Mechanism of Action of Bactericidal Lipophosphonoxins.

Authors:  Natalya Panova; Eva Zborníková; Ondřej Šimák; Radek Pohl; Milan Kolář; Kateřina Bogdanová; Renata Večeřová; Gabriela Seydlová; Radovan Fišer; Romana Hadravová; Hana Šanderová; Dragana Vítovská; Michaela Šiková; Tomáš Látal; Petra Lovecká; Ivan Barvík; Libor Krásný; Dominik Rejman
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

7.  Clearance of Vancomycin-Resistant Enterococcus Concomitant With Administration of a Microbiota-Based Drug Targeted at Recurrent Clostridium difficile Infection.

Authors:  Erik R Dubberke; Kathleen M Mullane; Dale N Gerding; Christine H Lee; Thomas J Louie; Harriet Guthertz; Courtney Jones
Journal:  Open Forum Infect Dis       Date:  2016-06-20       Impact factor: 3.835

8.  Vancomycin-resistant Enterococcus faecium COLONIZATION and Clostridium difficile infection in a HEMATOLOGIC patient.

Authors:  Ivana Goić-Barišić; Marina Radić; Anita Novak; Žana Rubić; Nataša Boban; Boris Lukšić; Marija Tonkić
Journal:  Acta Clin Croat       Date:  2020-09       Impact factor: 0.780

9.  Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection.

Authors:  Shanlin Ke; Nira R Pollock; Xu-Wen Wang; Xinhua Chen; Kaitlyn Daugherty; Qianyun Lin; Hua Xu; Kevin W Garey; Anne J Gonzales-Luna; Ciarán P Kelly; Yang-Yu Liu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

10.  Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes.

Authors:  Jure Skraban; Saso Dzeroski; Bernard Zenko; Domen Mongus; Simon Gangl; Maja Rupnik
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.